GALDERMA 2024: Phase III trials of RelabotulinumtoxinA show favorable outcomes and extended effectiveness in addressing both glabellar lines and lateral canthal lines at once.

Aviceda Therapeutics Reveals Preliminary Results from Initial Segment of Phase 2/3 SIGLEC Study on AVD-104, Indicating Encouraging Safety Profile and Initial Efficacy Signals in Individuals with Geographic Atrophy.

In molecular and microbiology, a vector refers to a method or agent that transports genetic material into a cell or organism.

Aruna Bio has received FDA approval for its investigational new drug (IND) application, allowing AB126, its pioneering exosome therapy.

In biology, a variant refers to a specific region of the genome that differs between two genomes, or an individual organism with characteristics that deviate from the standard within a species.

Sarepta Therapeutics Launches Participant Selection for Phase 3 Trial, EMERGENE, Investigating SRP-9003 in Limb-Girdle Muscular Dystrophy 2E/R4 Treatment.

Novartis Pharma will purchase SanReno Therapeutics, enhancing its kidney treatment range. Following the acquisition, SanReno will join Novartis China, advancing clinical trials of two important IgA nephropathy treatments, atrasentan and BION-1301.

CARsgen's candidate, CT011, has secured authorization from the NMPA to proceed with trials for GPC3-positive Ⅲa hepatocellular carcinoma patients with a significant risk of recurrence post-surgery.

The sponsor of a clinical trial, which may be a pharmaceutical company or an academic institution, is responsible for submitting information about their study to the ClinicalTrials.gov database.

Halozyme Reports Roche Granted EU Clearance for Subcutaneous Form of Tecentriq® with ENHANZE® Technology, Marking a Breakthrough in the Delivery of Immunotherapies Across Various Cancers.

On Jan 17, 2024, Windtree Therapeutics announced a licensing deal with Lee's Pharm for its heart failure drug istaroxime in Greater China.

Chipscreen NewWay Initiates Phase 1 Study: Administers Initial Dose of Innovative Dual-Targeting Antibody NWY001 for Advancing Cancer Immune Therapy in Individuals with Progressive Solid Cancers.